TCP
ITRM

Tourbillon Capital Partners’s Iterum Therapeutics ITRM Stock Holding History

Tourbillon Capital Partners’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6,602
Closed -$1.06M – 56
2018
Q2 		$1.06M Buy
+6,602
New +$1.19M 0.04% 73

Other funds holding ITRM

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
NA
Neuburgh Advisers Los Angeles, California $3.22B AUM 3.74% 1-Year Est. Return
FCM
Flinton Capital Management Philadelphia, Pennsylvania $3.22B AUM 4.75% 1-Year Est. Return

Tourbillon Capital Partners's ITRM Position: Q3 2018 in Review

Tourbillon Capital Partners sold out of Iterum Therapeutics (ITRM) in Q3 2018, closing a stake of 6,602 shares — an estimated $1.06M sold.

Tourbillon Capital Partners first reported a position in ITRM in Q2 2018 and held it in 1 quarter. The position peaked at $1.06M in Q2 2018. 21 funds tracked by Wall St. Rank hold ITRM as of Q3 2018.

  • Tourbillon Capital Partners reported no remaining Iterum Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Tourbillon Capital Partners sold 6,602 Iterum Therapeutics shares in Q3 2018, an estimated $1.06M.
  • Tourbillon Capital Partners first reported a position in Iterum Therapeutics in Q2 2018 and held it in 1 quarter.
  • Tourbillon Capital Partners's Iterum Therapeutics position peaked at $1.06M in Q2 2018.
  • 21 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2018.

Based on Tourbillon Capital Partners's 13F filing for Q3 2018, filed 14 Nov 2018.